| Literature DB >> 19292919 |
Pascalina Chanda1, Busiku Hamainza, Susan Mulenga, Victor Chalwe, Charles Msiska, Elizabeth Chizema-Kawesha.
Abstract
BACKGROUND: Zambia has taken lead in implementing integrated malaria control so as to attain the National Health Strategic Plan goal of "reducing malaria incidence by 75% and under-five mortality due to malaria by 20% by the year 2010". The strategic interventions include the use of long-lasting insecticide-treated nets and indoor residual spraying, the use of artemisinin-based combination therapies (ACT) for the treatment of uncomplicated malaria, improving diagnostic capacity (both microscopy and rapid diagnostic tests), use of intermittent presumptive treatment for pregnant women, research, monitoring and evaluation, and behaviour change communication. Financial barriers to access have been removed by providing free malaria prevention and treatment services.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19292919 PMCID: PMC2662870 DOI: 10.1186/1475-2875-8-49
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Facility visits for and malaria treatment
| Month | Number of visits for Under-five | Number positive (Parasite prevalence) | Total anti-malarial treatments |
| December 2007 | 378 | 2 (0.53%) | 6 (1.6%) |
| January 2008 | 638 | 7 (1.1%) | 13 (2.0%) |
| February 2008 | 362 | 1 (0.3)% | 6 (1.7%) |
| Total visits | 1378 | 10 (0.7%) | 25 (1.8%) |
Proportion of patients treated with a named drug
| Piriton | 396 | 28.7 |
| Amoxyl | 274 | 19.9 |
| ORS | 151 | 11.0 |
| Septrin | 145 | 10.5 |
| Pen V | 125 | 9.1 |
| Panadol | 114 | 8.3 |
| Flagyl | 48 | 3.5 |
| Coartem | 23 | 1.7 |
| Hydrocortisone | 22 | 1.6 |
| Nystatin | 17 | 1.2 |
| Phenergan | 13 | 0.9 |
| Cephalexin | 10 | 0.7 |
| Erythromycin | 9 | 0.7 |
| Clotrimazole | 8 | 0.6 |
| Procaine penicillin | 7 | 0.5 |
| Other | 16 | 1.2 |
Characteristics of single primary prescriptions
| Panadol | 114 | 35.3 |
| Prirton | 63 | 19.5 |
| ORS | 40 | 12.4 |
| Amoxyl | 36 | 11.1 |
| Pen V | 23 | 7.1 |
| TEO | 14 | 4.3 |
| Septrin | 12 | 3.7 |
| Phernergan | 5 | 1.5 |
| Coartem® | 5 | 1.5 |
| Cefalexin | 4 | 1.2 |
| Ciproflaxin | 4 | 1.2 |
| TSO | 1 | 0.3 |
| X-Pen | 1 | 0.3 |
| Griseofulvin | 1 | 0.3 |
Figure 1Trends in parasite rates among fever patients at Chongwe health facility 2003–2008.